
Concert Pharmaceuticals CNCE
Concert Pharmaceuticals General and Administrative Expenses | CNCE
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Concert Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 22.5 M | 18.9 M | 20.3 M | 22.9 M | 21 M | 14.4 M | 13.1 M | 11.7 M | 8.03 M | 7.27 M | 7.38 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | 7.27 M | 15.2 M |
Quarterly General and Administrative Expenses Concert Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 5.25 M | 4.85 M | 5.54 M | - | 5.46 M | 5.61 M | 5.48 M | - | 4.51 M | 4.73 M | 4.67 M | - | 4.74 M | 4.98 M | 5.61 M | - | 6.32 M | 5.51 M | 5.63 M | - | 4.88 M | 5.71 M | 5.25 M | - | 3.44 M | 3.83 M | 3.58 M | - | 3.27 M | 3.3 M | 3.23 M | - | 3.46 M | 2.72 M | 2.54 M | - | 2.13 M | 2.27 M | 1.96 M | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.32 M | 1.96 M | 4.35 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
56 M | - | - | $ 8.42 M | ||
|
ESSA Pharma
EPIX
|
13.2 M | - | - | $ 8.86 M | ||
|
Generation Bio Co.
GBIO
|
37.8 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
11.8 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
82.8 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
28.9 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
31.7 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
8.67 M | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
147 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
497 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
3.65 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
3.64 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
16.3 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
10.9 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
16.6 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
19.8 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
15.8 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
15.6 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
203 M | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
259 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
12.2 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
150 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
7.48 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
12.2 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
116 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
10.1 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
20.6 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
7.98 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
2 M | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
7.96 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
19.7 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
11.2 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
168 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
10.7 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
23.4 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
12.2 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
19 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
14.7 M | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
37.8 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
191 M | $ 84.95 | 0.13 % | $ 7.99 B |